Complete your personal information for a more tailored experience
Home
NEW: The STAT Mini
Take a break from the news and try our new weekly crossword.
By Adam Feuerstein
Dec. 7, 2025
Senior Writer, Biotech
Adam Feuerstein
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
ORLANDO, Fla. — With sales of its existing blood cancer CAR-T therapies weakening, Gilead Sciences needs anito-cel, its next CAR-T therapy for multiple myeloma, to succeed more than ever. 
On Saturday at the annual meeting of the American Society of Hematology, the company and its partner Arcellx reported deepening and durable responses with no concerning safety issues in the latest analysis of a pivotal-stage clinical trial.
Advertisement
Among 117 patients enrolled in the study, 96% showed a tumor response, with 74% of patients achieving complete remission, the companies said in a press release. 
STAT+ Exclusive Story
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
Adam Feuerstein
Senior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
By Adam Feuerstein, Damian Garde, and Katherine MacPhail
By Adam Feuerstein
Advertisement
By Meghana Keshavan
By Elaine Chen
By Jonathan Wosen

By Lizzy Lawrence

By Allison DeAngelis

By Megan Molteni, Anil Oza, and J. Emory Parker

By Lizzy Lawrence

By O. Rose Broderick
Share options
X
Bluesky
LinkedIn
Facebook
Doximity
Copy link
Reprints
A decade of reporting from the frontiers of health and medicine
Company
Account
More

source